# Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

> **NCT03443856** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 197 (actual)

## Conditions studied

- Gastric and Esophagogastric Junction Adenocarcinoma

## Interventions

- **DRUG:** Nivolumab and Ipilimumab
- **OTHER:** chemotherapy

## Key facts

- **NCT ID:** NCT03443856
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-17
- **Primary completion:** 2023-12-12
- **Final completion:** 2026-06
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03443856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03443856, "Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03443856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*